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We congratulate Dr Bush for establishing endovenous laser
treatment so sucessfully as an ambulatory procedure. His report on
350 treated limbs with respect to the safety of the method corrob-
orates our experience with similar numbers. However, at least two
issues mentioned in his letter deserve further consideration.
One, studies comparing varying laser pulse energy and laser
pulse duration with respect to success and side effects of the
method are lacking so far. Obviously, the work of Bush is very
important; therefore, it would be most welcome to see original
data on the optimal laser treatment protocol in more detail.
Particularly the “resealing” phenomenon described by Bush seems
to be of interest.
Second, rates of short-term and long-term treatment failure
are necessary to be determined by standardized follow-up proto-
cols, to identify patients most suitable for this kind of therapy and
also to determine those who benefit less. In our patient cohort
including all kind of patients (C2-C6, EP,S, AS,D, PR), with compa-
rable numbers and follow-up intervals as mentioned by Bush, at
least some medical conditions associated with heavy anticoagula-
tion treatment like coumadin seem to prone the patient for treat-
ment failure or early recannalization of the treated vein.
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